Hair-Loss Treatments: A Guide to the Evidence
Comparing established, adjunctive and experimental options without confusing diagnosis, approval and treatment outcomes.
Diagnosis first
Androgenetic alopecia, telogen effluvium, alopecia areata and scarring alopecias are different conditions. History, trichoscopy and selected tests guide treatment.
More established evidence
Topical minoxidil and finasteride in suitable men have substantial evidence for androgenetic alopecia. Licensing of dutasteride and oral minoxidil varies by country.
Adjunctive approaches
PRP, microneedling and low-level light have shown benefits in some studies. Variable protocols mean results cannot be assumed identical for everyone.
Limited or experimental approaches
Claims for vitamin mesotherapy, exosomes and cellular products must reflect the evidence. Commercial promotion cannot replace controlled research.
Alongside transplantation
Medication can preserve native hair; surgery redistributes donor grafts. These are different biological objectives.
Limits of the evidence
These are selected clinical sources and expert recommendations, not a new systematic review. Formulations, participants, controls, follow-up and adverse-event reporting differ. Positive findings do not establish identical benefit or local authorisation for every patient or product.
Treatment evidence map
This is a general editorial comparison for androgenetic alopecia (AGA) only, not a GRADE assessment or a new systematic review.
| Option | General AGA evidence | Main limitation | Safety issue |
|---|---|---|---|
| Topical minoxidil | Established controlled-trial support | Long-term use, variable response | Dermatitis, unwanted hair |
| Oral finasteride | Established evidence in men | Not generalisable to all groups | Sexual and mood effects; EMA warning |
| Dutasteride | Controlled comparisons and consensus | AGA licensing varies by country | Sexual effects, slow elimination |
| Low-dose oral minoxidil | Growing clinical evidence | Off-label use, systemic risks | Oedema, pulse and pressure changes |
| PRP | Positive trials and reviews | Preparation and session variability | Injection complications |
| Microneedling + minoxidil | Positive RCT meta-analysis | High heterogeneity | Infection, irritation |
| LLLT / LED | Some controlled trials | Devices are not equivalent | Eye and device safety |
| Vitamin mesotherapy | Insufficient strong evidence | Mixtures are not standardised | Infection, allergy |
| Intradermal dutasteride | Limited and variable studies | Protocols and long-term data | Systemic absorption, injections |
| Exosomes | Early research; not standard | Product quality and long-term safety | Unapproved products, contamination |
| Stem-cell derivatives | Experimental and heterogeneous | Different products are not equivalent | Regulatory and biological risks |
| Spironolactone | Some clinical evidence in women | Patient groups differ | Pregnancy, hyperkalaemia |
| Ketoconazole shampoo | Limited for AGA; established for dermatitis | Not equivalent to established AGA drugs | Irritation |
| Supplements | Targeted benefit in deficiency | Weak evidence without deficiency | Excess intake, test interference |
Topic-specific questions
Does an expert recommendation mean a product is locally approved?
No. Evidence, consensus and country-specific authorisation are separate questions.
Can evidence for AGA be applied to every form of shedding?
No. Diagnosis changes the treatment target and the relevant evidence.
Scientific references
- Rosenthal A et al. Management of androgenic alopecia: a systematic review of the literature. J Cosmet Laser Ther. 2024. DOI: 10.1080/14764172.2024.2362126. https://pubmed.ncbi.nlm.nih.gov/38852607/
- Landells I et al. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. J Cutan Med Surg. 2025. DOI: 10.1177/12034754251368849. https://pubmed.ncbi.nlm.nih.gov/40986632/
- Vañó-Galván S et al. A Consensus Statement From the Spanish Hair Disorders Group of the Spanish Academy of Dermatology and Venereology on the Management of Androgenetic Alopecia. 2024. https://doi.org/10.1016/j.ad.2023.10.043
- American Academy of Dermatology. Hair loss: Diagnosis and treatment. https://www.aad.org/public/diseases/hair-loss/treatment/diagnosis-treat
- US Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes